Daily Bio News Summary — 2026-08-17: AstraZeneca bispecific fail headlines a 32-item Monday

Monday’s biopharma news cycle is dominated by a single-day dual from AstraZeneca — a high-profile volrustomig bispecific discontinuation in lung cancer alongside separate late-stage wins for Tagrisso and Enhertu in the same indication — plus a China approval for Summit/Akeso’s PD-1xVEGF ivonescimab that came bundled with longer-follow-up survival data showing a smaller benefit than previously reported. The harvest parser pulled 220 article cards across the eleven homepages; 193 cleared the 30-day freshness filter, 22 were flagged paywalled at parse time, and 46 were genuinely new after URL dedupe against the existing 1,793 news files. Of those, the political / opinion-piece denylist (Rule 7) removed 8 items — including several STAT News first-person opinion pieces, Pharmaphorum and Endpoints Trump-MMR coverage, and the STAT News CMS gender-affirming-care piece — and one byline-as-title STAT item was filtered. Manual Tier 2 canonical-source dedupe then collapsed four duplicate-story clusters, dropping the Fierce Pharma and BioSpace AZ-bispecific-fail versions in favor of Endpoints, and keeping Endpoints over BioSpace for the Summit/Akeso China approval. What follows describes the 32 items that cleared curation.

AstraZeneca’s volrustomig bispecific discontinuation dominates

Endpoints News reports that AstraZeneca discontinued its late-stage volrustomig bispecific trial after a lung cancer efficacy setback (Endpoints News, 2026-08-17). The same day, AstraZeneca announced separate late-stage lung cancer trial wins for Tagrisso and Enhertu, distinct from the volrustomig failure. Fierce Biotech and BioSpace carried parallel coverage. The Fierce Pharma headline combined the wins-and-fail in a single article, while Fierce Biotech and BioSpace framed the discontinuation as extending AZ’s “losing streak” in lung cancer. The ICER cost-effectiveness determination on a separate AstraZeneca blood-pressure medication (Endpoints News, 2026-08-15) rounds out the day’s AZ coverage.

Summit/Akeso ivonescimab China approval with smaller-than-expected survival benefit

Endpoints News reports Summit Therapeutics and Akeso’s PD-1xVEGF bispecific ivonescimab won a new approval in China, but longer-follow-up data showed a smaller survival benefit than expected (Endpoints News, 2026-08-17). BioSpace carried a separate story emphasizing the survival benefit degradation. The story is structurally significant because ivonescimab is Summit’s flagship Phase 3 asset outside of China and the China approval had been widely anticipated as a positive catalyst; the smaller-benefit caveat introduces uncertainty into the upcoming global Phase 3 readout. A new akesobio.json company profile was created.

Eli Lilly’s $370M OmniAb deal and the Slate/Fulcrum reverse merger

Endpoints News reports Eli Lilly will pay up to $370M to collaborate with OmniAb on ion channel drug discovery; separately, Slate and Fulcrum are forging a reverse merger to join Nasdaq with $245M for migraine trials (Endpoints News, 2026-08-17). Fierce Biotech covered the OmniAb collab separately. The Slate/Fulcrum story is notable because Fulcrum Therapeutics has been operating as a publicly-listed rare-disease company; the “Vault” reverse-merger structure allows Slate Medicines to list without a traditional IPO. A new fulcrum-therapeutics.json profile was created; slate-medicines.json already exists.

EyePoint Phase 3 AMD failure sends stock spiraling

Both Reuters Biopharma and BioSpace reported that EyePoint Pharmaceuticals’ AMD drug failed a late-stage trial, sending shares tumbling (Reuters, 2026-08-17; BioSpace, 2026-08-17). The story matters because EyePoint’s lead asset DURAVYU was positioned as a next-generation sustained-release VEGF inhibitor for wet AMD. The Reuters headline frames it as “shares tank”; the BioSpace headline frames it as “stock spiraling amid next-gen AMD race.” A new eyepoint-pharmaceuticals.json profile was created.

Argenx Vyvgart Hytrulo Phase 3 win in autoimmune myositis

Endpoints News reports Argenx announced a Phase 3 win for Vyvgart Hytrulo in autoimmune myositis, setting up a potential next indication nod (Endpoints News, 2026-08-17). Fierce Pharma ran a parallel story framing Argenx as “preps next potential Vyvgart nod after ph. 3 win.” Autoimmune myositis is a sizable unmet-need indication and would expand Vyvgart’s already-broad label.

Other notable items

• Cytokinetics filed a patent infringement lawsuit against Bristol Myers Squibb, escalating competition in the cardiac myosin modulator space (Endpoints News, 2026-08-15).
• Capricor Therapeutics plans to ask FDA to review additional data for its Duchenne muscular dystrophy therapy (Endpoints News, 2026-08-15).
• Biogen’s monoclonal antibody felzartamab received its first global approval in China (Endpoints News, 2026-08-15).
• Abcuro raised $66M to advance its Phase 3 program in inclusion body myositis (Endpoints News, 2026-08-15).
• Redx Pharma is pursuing another reverse merger, this time with Skye Bioscience (Endpoints News, 2026-08-15).
• Vogenx raised $81M in its IPO to fund a Phase 2 trial for post-bariatric hypoglycemia (PBH) with mizagliflozin (MedCity News, 2026-08-01).
• Sandoz will license three biosimilar drugs from Shanghai Henlius Biotech (Reuters, 2026-08-17). New sandoz.json and henlius-biopharmaceuticals.json profiles were created.
• Reuters Breakingviews analyzes how Eli Lilly has become pharma’s latest “victim of success” as its growth strains capacity and pricing dynamics (Reuters, 2026-07-30).
• Evaxion scrapped its solid tumor vaccine program to focus on a Duke-partnered brain cancer candidate (Fierce Biotech, 2026-08-17).
• Acurx Pharmaceuticals received FDA conditional acceptance and a USPTO trademark allowance for ibezapolstat (PR Newswire FDA, 2026-08-17).
• AbelZeta Pharma regained global rights to C-CAR039 (Prizlon-cel) and received FDA clearance of an IND application in large B-cell lymphoma (PR Newswire FDA, 2026-08-16).
• Vera Therapeutics’ newly approved IgA nephropathy drug supports kidney function like Otsuka’s Voyxact (BioSpace, 2026-08-12).
• Johnson & Johnson returned rights to its lymphoma bispecific CAR-T therapy back to AbelZeta (BioSpace, 2026-08-12).
• Aurisco Pharmaceutical became the first generic oligonucleotide manufacturer in the world successfully inspected by USFDA (PR Newswire FDA, 2026-08-12).
• Photocure welcomed an FDA proposal to reclassify blue light cystoscopy systems from Class III to Class II (PR Newswire FDA, 2026-08-14).
• Nolla Health expanded its medical advisory board (PR Newswire FDA, 2026-08-17).
• STAT News ran an opinion piece on paid paternity leave as pediatric preventive care.
• Fierce Biotech raised questions about whether China’s IIT (Investigator-Initiated Trial) pathway can still be trusted after two undisclosed gene therapy deaths.
• BioSpace reported Italian biotech companies are gaining momentum as VC funding and tech transfer environments improve.
• European regulators pulled Tavneos (avacopan) citing incorrect and misleading data (Endpoints News, 2026-08-14).
• STAT News covered Luigi Mangione’s guilty plea to federal stalking charges in the killing of UnitedHealthcare CEO Brian Thompson.

Eleven new company profiles created

• EyePoint Pharmaceuticals (NASDAQ: EYPT) — ophthalmology biotech focused on sustained-release therapeutics for AMD.
• Sandoz (SIX: SDZ) — global biosimilars and generics leader spun off from Novartis.
• Henlius Biopharmaceuticals (HKEX: 2696) — Chinese biosimilars and oncology biologics company.
• Fulcrum Therapeutics (NASDAQ: FULC) — rare-disease company developing small molecules for FSHD and sickle cell.
• Evaxion (NASDAQ: EVAX) — Danish AI-driven immunotherapy company.
• AbelZeta Pharma — clinical-stage CAR-T and immuno-oncology company (Rockville, MD).
• Akesobio (HKEX: 9926) — Chinese antibody company developing the PD-1xVEGF bispecific ivonescimab.
• Abcuro — clinical-stage immunotherapy company developing treatments for autoimmune diseases.
• Redx Pharma — UK precision-oncology and fibrosis company.
• Cytokinetics (NASDAQ: CYTK) — cardiac and skeletal muscle biology therapeutics.
• Acurx Pharmaceuticals (NASDAQ: ACXP) — antibiotics developer for C. difficile.

What this batch is NOT telling us

Several structural absences: (a) no FDA Newsroom press-release items landed as the canonical source for any of today’s items — every regulatory story came via the trade press; (b) no BioPharma Dive articles cleared the per-site date parser (the Dive homepage format issue covered in prior pitfall logs); (c) no STAT News clinical-readout reporting made the cut today; (d) Fierce Pharma and Fierce Biotech contributed heavily to the AZ-bispecific-fail cluster but were dropped from that cluster in favor of the higher-priority Endpoints version; (e) the political-denylist hits today included two STAT “Trump-administration” pieces that the script keyword set did not catch initially — these were caught by the URL-pattern denylist (\btrump\b) and the ^we (proved|need|...)\b first-person framing pattern that I added during the curation script.

Reading order for limited time

1. The AstraZeneca volrustomig discontinuation + Tagrisso/Enhertu wins — most consequential clinical news of the day.
2. The Summit/Akeso ivonescimab China approval with smaller-benefit caveat — the second-largest catalyst with the most negative framing.
3. The EyePoint AMD Phase 3 fail — relevant for the wet-AMD competitive landscape.
4. The Eli Lilly / OmniAb $370M deal — illustrates the breadth of Lilly’s BD strategy.
5. The Argenx Vyvgart Hytrulo Phase 3 — relevant for the autoimmune neuromuscular space.

How to read the underlying articles

Every news file lives at src/content/news/<slug>.md with frontmatter-only content; sourceUrl is the canonical link to the original article on the source site, and pubDate is the parse-verified publication date. Company profiles at src/content/companies/<slug>.json are sourced from jobscraper.db for the careers section and from a one-shot web enrichment pass for headquarters, founded, sector, and website. Today’s run wrote 32 news files and 11 company profiles. Numbered citation list follows:

1. evaxion-scraps-tumor-vaccine-to-focus-on-brain-cancer-candidate.md (Fierce Biotech, 2026-08-17)
2. after-2-undisclosed-deaths-can-china-s-iit-still-be-trusted.md (Fierce Biotech, 2026-08-17)
3. slate-uses-fulcrum-to-join-nasdaq-with-245m-for-migraine-trials.md (Fierce Biotech, 2026-08-17)
4. argenx-preps-next-potential-vyvgart-nod-after-ph-3-win.md (Fierce Pharma, 2026-08-17)
5. eyepoint-s-drug-for-age-related-eye-disease-fails-late-stage-trial-shares-tank.md (Reuters Biopharma, 2026-08-17)
6. sandoz-to-license-three-biosimilar-drugs-from-shanghai-henlius-biotech.md (Reuters Biopharma, 2026-08-17)
7. eyepoint-s-phase-3-fail-sends-stock-spiraling-amid-next-gen-amd-race.md (BioSpace, 2026-08-17)
8. summit-and-akeso-s-pd-1xvegf-bispecific-got-a-new-approval-in-china-it-came-with-an-unwelcome-surprise.md (Endpoints News, 2026-08-17)
9. astrazeneca-touts-separate-late-stage-lung-cancer-wins-with-tagrisso-enhertu.md (Endpoints News, 2026-08-17)
10. astrazeneca-cans-late-stage-bispecific-trial-after-lung-cancer-setback.md (Endpoints News, 2026-08-17)
11. celcuity-awaits-fda-review-for-second-factory-to-launch-cancer-drug.md (Endpoints News, 2026-08-17)
12. argenx-declares-phase-3-win-for-vyvgart-hytrulo-in-autoimmune-myositis.md (Endpoints News, 2026-08-17)
13. lilly-to-pay-up-to-370m-for-omniab-collab-slate-fulcrum-forge-reverse-merger.md (Endpoints News, 2026-08-17)
14. acurx-pharmaceuticals-receives-fda-conditional-acceptance-and-uspto-trademark-allowance-for-the-company-s-brand-name-for-ibezapolstat.md (PR Newswire FDA, 2026-08-17)
15. nolla-health-expands-medical-advisory-board-and-clinical-leadership-to-help-shape-the-future-of-ai-powered-healthcare.md (PR Newswire FDA, 2026-08-17)
16. paid-paternity-leave-is-pediatric-preventive-care.md (STAT News, 2026-08-17)
17. abelzeta-regains-global-rights-of-c-car039-prizlon-cel-and-receives-fda-clearance-of-ind-application-in-large-b-cell-lymphoma.md (PR Newswire FDA, 2026-08-16)
18. photocure-welcomes-fda-proposal-to-initiate-the-reclassification-of-blue-light-cystoscopy-systems-from-class-iii-to-class-ii.md (PR Newswire FDA, 2026-08-14)
19. incorrect-and-misleading-data-prompted-regulators-decision-to-pull-tavneos-in-europe.md (Endpoints News, 2026-08-14)
20. luigi-mangione-pleads-guilty-to-federal-stalking-charges-in-the-killing-of-unitedhealthcare-ceo.md (STAT News, 2026-08-14)
21. icer-says-astrazeneca-s-new-blood-pressure-med-isn-t-cost-effective.md (Endpoints News, 2026-08-15)
22. abcuro-gets-66m-for-phase-3-in-muscle-weakening-condition.md (Endpoints News, 2026-08-15)
23. redx-tries-again-at-reverse-merger-with-skye-this-time-as-route-gains-steam.md (Endpoints News, 2026-08-15)
24. cytokinetics-brings-patent-suit-against-bristol-myers-escalating-rivalry.md (Endpoints News, 2026-08-15)
25. capricor-seeking-lifeline-for-duchenne-therapy-says-it-will-ask-fda-to-review-additional-data.md (Endpoints News, 2026-08-15)
26. biogen-s-monoclonal-antibody-felzartamab-wins-first-global-approval-in-china.md (Endpoints News, 2026-08-15)
27. vera-s-newly-approved-iga-nephropathy-drug-supports-kidney-function-like-otsuka-s-voyxact.md (BioSpace, 2026-08-12)
28. j-j-hands-lymphoma-bispecific-car-t-back-to-abelzeta.md (BioSpace, 2026-08-12)
29. italian-biotech-gains-momentum-as-vc-funding-tech-transfer-environment-improve.md (BioSpace, 2026-08-12)
30. aurisco-pharmaceutical-is-the-first-generic-oligonucleotide-manufacturer-in-the-world-successfully-inspected-by-usfda.md (PR Newswire FDA, 2026-08-12)
31. vogenx-ipo-raises-81m-for-trial-in-metabolic-disease-with-no-approved-drugs.md (MedCity News, 2026-08-01)
32. eli-lilly-is-pharma-s-latest-victim-of-success.md (Reuters Biopharma, 2026-07-30)